<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40388724</article-id><article-id pub-id-type="pmc">PMC12091660</article-id>
<article-id pub-id-type="publisher-id">MD-D-25-00709</article-id><article-id pub-id-type="art-access-id">00005</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000042379</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>4300</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Association between circulating inflammatory proteins and gout: A Mendelian randomization study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-5364-7808</contrib-id><name><surname>Xie</surname><given-names>Xiaochao</given-names></name><degrees>MM</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Yanjie</given-names></name><degrees>MM</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wenwen</given-names></name><degrees>MM</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Hui</given-names></name><degrees>BM</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Nan</given-names></name><degrees>MM</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1135-5224</contrib-id><name><surname>Wang</surname><given-names>Fang</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label> Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, People&#x02019;s Republic of China</aff><aff id="aff2"><label>b</label> Department of Endocrinology, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, People&#x02019;s Republic of China</aff><aff id="aff3"><label>c</label> Department of Cardiology, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, People&#x02019;s Republic of China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Fang Wang, Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, People&#x02019;s Republic of China (e-mail: <email xlink:href="18660291711@qdu.edu.cn">18660291711@qdu.edu.cn</email>).</corresp></author-notes><pub-date pub-type="collection"><day>16</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2025</year></pub-date><volume>104</volume><issue>20</issue><elocation-id>e42379</elocation-id><history><date date-type="received"><day>15</day><month>1</month><year>2025</year></date><date date-type="received"><day>17</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="medi-104-e42379.pdf"/><abstract><p>Clinical studies have consistently demonstrated that inflammation is a critical factor in the pathophysiology and progression of gout. This study aims to explore the causal relationship between CIPs and gout, utilizing MR in conjunction with meta-analyses. We utilized genetic data pertaining to gout from the GWAS which involved 3576 cases and 147,221 control participants. A total of 132 CIPs were extracted from the GWAS data to identify SNPs associated with gout. The primary analytical approach was the IVW method. Sensitivity analyses indicated no pleiotropy or heterogeneity. The IVW results revealed that several CIPs were associated with gout in European populations. The analysis results indicate that FGF-21, MMP-1, G-CSF, and IFN-&#x003b3; are involved in the pathogenesis of gout, and gout may influence the expression of CXCL1, IL-1Ra, and TNF-&#x003b1;. Consequently, targeted research focusing on specific CIPs could provide a promising strategy for the treatment and prevention of gout, offering potential therapeutic targets for the underlying inflammatory mechanisms of the disease.</p></abstract><kwd-group><kwd>bidirectional</kwd><kwd>circulating inflammatory proteins</kwd><kwd>gout</kwd><kwd>Mendelian randomization</kwd><kwd>meta-analysis</kwd></kwd-group><funding-group><award-group id="ID0EHGAG141563"><funding-source>the Qingdao Municipal Medical and Health Research Guidance Project</funding-source><award-id>2024-WJKY039</award-id><principal-award-recipient>Xiaochao Xie</principal-award-recipient></award-group><award-group id="ID0EMQAG141562"><funding-source>the National Traditional Chinese Medicine Comprehensive Reform Demonstration Zone Technology Co-construction Project</funding-source><award-id>GZY-KJS-SD-2024-004</award-id><principal-award-recipient>Xiaochao Xie</principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Gout is a disorder characterized by inflammation of the joints due to elevated levels of uric acid in the body. This disorder results from dysregulation in purine metabolism, leading to the accumulation of monosodium urate (MSU) crystals within and around the articular structures. The deposition of these crystals triggers an inflammatory response, ultimately resulting in gouty arthritis.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Recent evidence has increasingly highlighted the central role of chronic inflammation in the pathogenesis of gout. Over the past 2 decades, significant progress has been made in understanding the innate immune mechanisms that drive gouty inflammation. The gold standard for diagnosing gout remains the identification of MSU crystals in gouty tophi via microscopy.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup></p><p>It has been well established that the deposition of MSU crystals in the joints triggers the activation of immune cells, including macrophages, neutrophils, and monocytes. These cells release a range of circulating inflammatory proteins (CIPs), such as tumor necrosis factor-alpha (TNF-&#x003b1;), interleukin-1&#x003b2; (IL-1&#x003b2;), interleukin-6 (IL-6), and interleukin-18 (IL-18), which initiate and amplify the inflammatory cascade that underpins the pathogenesis of gout.<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>]</sup> Among these, the interleukin-1(IL-1) family of cytokines is particularly critical, playing a pivotal role in both innate immunity and the regulation of inflammatory processes. IL-1 family members mediate immune responses through diverse mechanisms, including the processing and secretion of precursor proteins, modulation of gene expression, and interaction with specific receptors.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> The IL-1 family consists of 13 members, including IL-1&#x003b2;, IL-6, and IL-18, all of which are involved in the inflammatory response associated with gout. Furthermore, TNF-&#x003b1; is another key pro-inflammatory cytokine that contributes significantly to the exacerbation of gout attacks. Collectively, these inflammatory mediators intensify both the inflammatory response and the pain associated with gout through complex signaling pathways and cell-to-cell interactions. A deeper understanding of the mechanisms by which these inflammatory factors exert their effects is crucial for the development of novel therapeutic strategies, such as the use of IL-1&#x003b2; antagonists (e.g., anakinra) to mitigate the symptoms of gout.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> However, research on the role of other CIPs in gout remains limited. Moreover, establishing causal relationships between specific cytokines and gout is challenging, owing to the confounding factors and reverse causality inherent in clinical and observational studies.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup></p><p>Mendelian Randomization (MR) is a research methodology that leverages genetic variation as instrumental variables (IVs) to assess causal relationships between risk factors and specific diseases.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> In MR analysis, genetic variation adheres to the principle of random allele distribution during meiosis, akin to the randomization process in controlled trials. Consequently, this approach mitigates several limitations inherent in observational studies, such as confounding, reverse causality, and selection bias, while also circumventing the logistical constraints of randomized controlled trials. Previous studies have demonstrated that genetic variation in individuals can influence the incidence, progression, and clinical outcomes of gout, with identified genetic polymorphisms potentially modulating both the risk and severity of the disease. To date, MR has not been applied to explore the causal relationship between CIPs and gout.</p><p>In this study, we employ two-sample MR analysis to investigate the causal relationships between multiple CIPs and the development of gout, and integrate data from Genome-wide Association Study (GWAS) with MR analysis to investigate the causal associations between various CIPs and the risk of gout. The aim of this study is to clarify the role of CIPs in gout pathogenesis and to establish a theoretical framework for future research on potential pharmacological targets for gout, which is of considerable clinical significance.</p></sec><sec sec-type="methods"><title>2. Materials and methods</title><sec><title>2.1. Ethics statement</title><p>Our study involved human participants&#x02019; data which are from the IEU open GWAS project and the EBI GWAS Catalog project (obtained date: October 07, 2024). The data from these 2 projects are publicly available. Ethical approval was not necessary for our study.</p></sec><sec><title>2.2. Study design</title><p>MR is based on 3 fundamental assumptions: relevance: the IVs used in the study must be strongly associated with the exposure factor; independence: the IVs must be independent of any confounding factors that could influence the exposure-outcome relationship; and exclusion restriction: the exposure factor should be the sole pathway through which the IVs affect the outcome.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> To comprehensively identify CIPs associated with gout, this study conducted an extensive screening of GWAS data, resulting in a dataset comprising 41 previously published CIPs and 91 newly identified CIPs.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup>To further explore the causal relationship between CIPs and gout, we performed a bidirectional MR analysis. In the forward MR analysis, CIPs were treated as exposure factors, with gout as the outcome variable, to assess the causal link between CIPs and gout. In the reverse MR analysis, gout was considered as the exposure factor and CIPs as the outcome variable, enabling the investigation of the potential causal influence of gout on CIPs, as illustrated in Figure <xref rid="F1" ref-type="fig">1</xref>.</p><fig position="float" id="F1"><label>Figure 1.</label><caption><p>Bidirectional MR research flowchart for CIPs and gout. This figure elucidates the 3 foundational assumptions of MR: (1) Relevance: SNPs robustly associated with exposure, independence, and exclusion restriction; (2) Independence: SNPs not associated with confounders; (3) Exclusion restriction: SNPs only associated with outcome through exposure. CIPs = circulating inflammatory proteins, IVs = instrumental variables, SNPs = single nucleotide polymorphisms, MR = Mendelian randomization.</p></caption><graphic xlink:href="medi-104-e42379-g001" position="float"/></fig></sec><sec><title>2.3. Data source</title><p>The GWAS data for 91 CIPs were obtained from 14,824 participants of European ancestry across 11 independent cohorts, and a genome-wide protein quantitative trait loci (pQTL) analysis was performed for these 91 CIPs.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> These data are available through the EBI GWAS Catalog project (IDs ranging from GCST90274758 to GCST90274848).</p><p>The GWAS data for 41 inflammatory factors were derived from combined analyses of 3 independent cohorts, comprising a total of 8293 Finnish participants.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> These data can be accessed via the MRC IEU open GWAS project (IDs ebi-a-GCST004420 to ebi-a-GCST004460).</p><p>Single nucleotide polymorphisms (SNPs) associated with gout were extracted from the FinnGen database, which includes 3576 European cases and 147,221 controls. This dataset is also available for download from the IEU open GWAS project (ID finn-b-M13_GOUT). Since the data used in this study are publicly available from GWAS databases, ethical approval and informed consent were not required.</p></sec><sec><title>2.4. Selection of IVs</title><p>To satisfy the first MR assumption regarding the strong association between SNPs and cytokines, it is crucial to select SNPs that are significantly associated with CIPs at the genome-wide level (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10&#x0207b;&#x02078;). However, it is important to acknowledge the limitations of using this stringent threshold for SNP selection in certain human phenotypes. In the context of this bidirectional MR analysis, we encountered such limitations when applying the <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10&#x0207b;&#x02078; threshold. To obtain more robust IVs, we relaxed the genome-wide significance threshold and set the SNP inclusion criterion to <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10&#x0207b;&#x02076;.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> Relaxation of the genome-wide significance threshold followed previously validated approaches for MR analyses with limited instrument strength.<sup>[<xref rid="R13" ref-type="bibr">13</xref>&#x02013;<xref rid="R20" ref-type="bibr">20</xref>]</sup> To minimize the influence of linkage disequilibrium (LD) on our results, we implemented a two-stage LD pruning and clumping procedure based on established methodologies.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R21" ref-type="bibr">21</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref>]</sup> First, genome-wide LD pruning was performed using PLINK v1.9 &#x0201c;indep-pairwise&#x0201d; function<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> with a 10,000&#x02009;kb sliding window and stringent <italic toggle="yes">r</italic>&#x000b2; threshold of 0.001. This approach, recommended by Purcell et al for capturing long-range LD regions,<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> effectively removed redundant SNPs within the exposure dataset.</p><p>The selected parameters (10,000&#x02009;kb window; <italic toggle="yes">r</italic><sup>2</sup>&#x02005;&#x0003c;&#x02005;0.001) were validated by Burgess et al as optimal thresholds for ensuring SNP independence in Mendelian randomization studies.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup> To estimate the proportion of variance explained by each SNP for the exposure variable (i.e., the <italic toggle="yes">R</italic><sup>2</sup> value), the following formulas were applied:</p><disp-formula>
<mml:math id="M1" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mstyle/></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mtext>&#x02009;</mml:mtext></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math>
</disp-formula><p>The two formulas provided involve the effect allele frequency (EAF), where 1&#x02005;&#x02212;&#x02005;EAF represents the frequency of the non-effect allele, N denotes the sample size for the exposure variable, beta refers to the estimated genetic effect, and SE represents the standard error of the genetic effect. These formulas quantify the degree to which each SNP accounts for the variability in the exposure variable, with a higher <italic toggle="yes">R</italic><sup>2</sup> value indicating a stronger explanatory power of the SNP for the exposure. In MR, selecting SNPs with higher <italic toggle="yes">R</italic><sup>2</sup> values as instrumental variables typically enhances both the statistical power and the reliability of the analysis. To assess the strength of genetic instrumental variables in MR, a higher <italic toggle="yes">F</italic>-statistic suggests a stronger SNP instrument, with a threshold value of 10 or greater considered indicative of a robust instrument.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup></p><p>To further ensure the validity of IVs, we performed rigorous quality control steps to exclude pleiotropic and weak instruments: Pleiotropy removal: SNPs showing significant associations (<italic toggle="yes">P&#x02005;</italic>&#x0003c;&#x02005;1&#x02005;&#x000d7;&#x02005;10&#x0207b;&#x02075;) with potential confounders were identified via PhenoScanner V2 and excluded. Horizontal pleiotropy was assessed using MR-Egger intercept test (<italic toggle="yes">P&#x02005;</italic>&#x0003e;&#x02005;.05) and MR-PRESSO global test (<italic toggle="yes">P&#x02005;</italic>&#x0003e;&#x02005;.05). Outlier SNPs detected by MR-PRESSO were iteratively removed. Weak instrument filtering: All retained SNPs had <italic toggle="yes">F</italic> statistics&#x02005;&#x0003e;&#x02005;10. SNPs with <italic toggle="yes">F</italic>&#x02005;&#x0003c;&#x02005;10 were excluded. Heterogeneity checks: Cochran&#x02019;s Q test indicated no significant heterogeneity among SNPs. Sensitivity analyses using leave-one-out method confirmed no single SNP drove the causal effect.</p><p>In this study, we assume that the selected genetic instruments satisfy the independence assumption, meaning that these instruments are not associated with any known or unknown confounders in the study. In other words, the variation in the instruments affects the outcome variable only through the exposure variable, and not through other potential confounding factors. To validate this assumption, we conducted a series of sensitivity analyses and ruled out factors that may affect the independence of the instruments.</p></sec><sec><title>2.5. Statistical analysis</title><p>This study employed bidirectional MR to assess causal relationships, utilizing the inverse variance weighted (IVW) method, which was widely regarded as the most effective approach in MR due to its high statistical power. Supplementary analyses were performed using the MR Egger, Weighted Median, Simple Mode, and Weighted Mode methods.<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> The odds ratio (OR) and its corresponding 95% CI derived from the bidirectional MR analysis were used to evaluate the causal effect of the exposure on the outcome. Various visualization tools, including forest plots, scatter plots, and funnel plots, were employed to present the results. Additionally, a circular heatmap was generated by combining <italic toggle="yes">P</italic> values from the 5 MR methods with the OR from the IVW method.</p><p>To evaluate the stability and reliability of the MR results, this study conducted multiple sensitivity analyses employing various methods. MR-Egger was used to assess and adjust for the potential influence of horizontal pleiotropy. A significant non-zero intercept in MR-Egger suggests the presence of interference from other factors on the effect of the instrumental variable on the outcome. By estimating the intercept, more reliable causal estimates can be obtained in the presence of pleiotropy, thereby reducing bias induced by pleiotropy.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> MR-PRESSO evaluates residuals and outliers of the instrumental variables to identify potential pleiotropic effects. If abnormal instrumental variables are identified, removing these outliers and applying corrections ensures more robust results.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> Additionally, a leave-one-out analysis was performed to assess the potential influence of individual SNPs on the MR estimates, thereby enhancing the reliability and stability of the results.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> To assess heterogeneity, Cochran&#x02019;s Q tests were conducted for both the IVW and MR-Egger methods. A <italic toggle="yes">P</italic> value below .05 indicates the presence of heterogeneity, which is assessed using a random-effects model, while a <italic toggle="yes">P</italic> value of .05 or greater is evaluated with a fixed-effects model.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> To reduce the probability of erroneously rejecting the null hypothesis due to multiple testing, Bonferroni correction was applied by dividing the original significance threshold by the number of independent tests. Therefore, a <italic toggle="yes">P</italic> value of less than 3.79&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;4</sup> (0.05/132) indicates a significant association, whereas <italic toggle="yes">P</italic> values between 3.79&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;4</sup> and 0.05 suggests a suggestive association.<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> Furthermore, a meta-analysis was conducted on the results from the same CIPs across 2 datasets.<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> Statistical analyses were performed using R software (version 4.4.0), with the following packages: TwoSampleMR, MendelianRandomization, circlize, ComplexHeatmap, tidyverse, ggpubr, and MRPRESSO.</p></sec><sec><title>2.6. Statistical power calculations</title><p>To evaluate the reliability of causal inferences, we performed statistical power calculations for all inflammatory factors included in the bidirectional MR analysis. Following the methodology of Burgess,<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> we estimated power based on the following parameters: Instrument strength: Genetic instruments were restricted to SNPs with <italic toggle="yes">F</italic>-statistics&#x02005;&#x0003e;&#x02005;10 to minimize weak instrument bias; Effect size range: We assumed OR from 1.1 to 1.5 for the exposure-outcome relationship; and Sample size: The sample sizes of both exposure and outcome GWAS datasets were incorporated into the power formula. Full results of these calculations are provided in Table S7, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O842" ext-link-type="uri">https://links.lww.com/MD/O842</ext-link> and Figure S7, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link>.</p></sec></sec><sec sec-type="results"><title>3. Results</title><p>The study incorporated a total of 133 GWASs, including 132 for CIPs and one for gout (Table S1, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O842" ext-link-type="uri">https://links.lww.com/MD/O842</ext-link>). The F-statistics for all instrumental variables were greater than 10, demonstrating the robustness of the selected SNPs (Table S2, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O842" ext-link-type="uri">https://links.lww.com/MD/O842</ext-link>).</p><sec><title>3.1. Causal effects of CIPs on gout</title><p>In the IVW analysis of forward MR, 5 CIPs were suggestively and positively associated with gout, including fibroblast growth factor 21 (FGF-21) (OR&#x02005;=&#x02005;1.203; 95% confidence interval [CI]: 1.002&#x02013;1.445; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.048), matrix metalloproteinases-1 (MMP-1) (OR&#x02005;=&#x02005;1.248; 95% CI: 1.061&#x02013;1.468; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.008), granulocyte colony-stimulating factor (G-CSF) (OR&#x02005;=&#x02005;1.234; 95% CI: 1.012&#x02013;1.506; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.038), interferon-gamma (IFN-&#x003b3;) (OR&#x02005;=&#x02005;1.295; 95% CI: 1.026&#x02013;1.634; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.029), and transforming growth factor alpha (TGF-&#x003b1;) (OR&#x02005;=&#x02005;1.305; 95% CI: 1.020&#x02013;1.669; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.034) (Fig. <xref rid="F2" ref-type="fig">2</xref>). The forest plot results from the IVW and MR-Egger analyses for these 5 CIPs are presented in Figure S1, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link>. Scatter plots suggested a positive correlation between these 5 CIPs and gout (Fig. <xref rid="F3" ref-type="fig">3</xref>). Bonferroni correction for multiple comparisons indicated that the association between these 5 CIPs and gout was positive (3.79&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;4</sup>&#x02005;&#x0003c;&#x02005;<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05). The &#x0201c;leave-one-out&#x0201d; analysis confirmed the robustness of the MR findings (Figure S2, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link>). The forest plot for the 132 CIPs using the IVW method in the forward MR analysis is shown in Figure S3, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link>, and the heatmap showing the 132 CIPs as exposures and gout as the outcome is presented in Figure <xref rid="F4" ref-type="fig">4</xref>.The results of the causal relationship between 132 CIPS and gout in the forward MR analysis are presented in Table S3, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O842" ext-link-type="uri">https://links.lww.com/MD/O842</ext-link>.</p><fig position="float" id="F2"><label>Figure 2.</label><caption><p>The positive results of the forward MR analysis conducted with the Inverse variance weighted, MR-Egger, Weighted median, Simple mode, and Weighted mode method. FGF21 = Fibroblast Growth Factor 21, MMP-1 = Matrix Metalloproteinases-1, nsnp = the number of single-nucleotide polymorphisms used in the analysis, OR = odds ratio.</p></caption><graphic xlink:href="medi-104-e42379-g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3.</label><caption><p>Scatter plots of the causal effects of CIPs associated SNPs on gout. (A) FGF21, Fibroblast Growth Factor 21; (B) MMP-1, Matrix metalloproteinase-1; (C) G-CSF, Granulocyte Colony-Stimulating Factor; (D) IFN-&#x003b3;, Interferon-gamma; (E) TGF-<sub>&#x003b1;</sub>, Transforming Growth Factor Alpha. CIPs = circulating inflammatory proteins, SNPs = single nucleotide polymorphisms.</p></caption><graphic xlink:href="medi-104-e42379-g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4.</label><caption><p>Circular heatmap of forward MR analysis. The circular heatmap, from outer to inner layers, represents the <italic toggle="yes">P</italic> values obtained from 5 MR methods (IVW, MR Egger, Weighted median, Simple mode, Weighted mode), with the innermost layer depicting the OR values obtained from the IVW method. IVW = Inverse variance weighted.</p></caption><graphic xlink:href="medi-104-e42379-g004" position="float"/></fig><p>The MR-Egger intercept analysis revealed no evidence of horizontal pleiotropy for FGF-21, MMP-1, G-CSF, and IFN-&#x003b3;, with intercepts of FGF-21 (intercept&#x02005;=&#x02005;&#x02212;0.040, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.106), MMP-1 (intercept&#x02005;=&#x02005;0.01, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.551), G-CSF (intercept&#x02005;=&#x02005;&#x02212;0.005, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.964), and IFN-&#x003b3; (intercept&#x02005;=&#x02005;0.034, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.291). However, horizontal pleiotropy was observed for TGF-&#x003b1; (intercept&#x02005;=&#x02005;0.073, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.017). MR-PRESSO results indicated no significant heterogeneity for these 5 CIPs, with FGF-21 (RSSobs&#x02005;=&#x02005;11.414, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.66), MMP-1 (RSSobs&#x02005;=&#x02005;13.968, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.685), G-CSF (RSSobs&#x02005;=&#x02005;5.515, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.784), IFN-&#x003b3; (RSSobs&#x02005;=&#x02005;10.58, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.343), and TGF-&#x003b1; (RSSobs&#x02005;=&#x02005;18.47, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.2) (Table <xref rid="T1" ref-type="table">1</xref>). Although the <italic toggle="yes">P</italic> value for TGF-&#x003b1; in MR-PRESSO was greater than .05, indicating no significant instrumental variable outliers or heterogeneity caused by outliers, the MR-Egger intercept analysis detected significant horizontal pleiotropy, suggesting that TGF-&#x003b1; may influence the outcome through pathways unrelated to the exposure. The use of uncorrected effect estimates could lead to bias.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> Therefore, TGF-&#x003b1; was considered to exhibit significant pleiotropy and was excluded from the forward results of the IVW analysis. All Cochran&#x02019;s Q test <italic toggle="yes">P</italic> values were greater than .05, indicating no heterogeneity; thus, all analyses were conducted using a fixed-effects model (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Heterogeneity test, pleiotropy test, and MR-PRESSO results for positive CIPs and gout in forward and reverse MR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Exposure</th><th align="center" rowspan="2" colspan="1">Outcome</th><th align="center" colspan="4" rowspan="1">Heterogeneity test</th><th align="center" colspan="3" rowspan="1">Pleiotropy test</th><th align="center" colspan="2" rowspan="1">MR-PRESSO</th></tr><tr><th align="center" rowspan="1" colspan="1">Method</th><th align="center" rowspan="1" colspan="1">Q</th><th align="center" rowspan="1" colspan="1">Q_df</th><th align="center" rowspan="1" colspan="1">Q_<italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Egger intercept</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Global test RSSobs</th><th align="center" rowspan="1" colspan="1">Global test <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">FGF21</td><td align="center" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">6.473</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">.84</td><td align="center" rowspan="2" colspan="1">&#x02212;0.04</td><td align="center" rowspan="2" colspan="1">0.023</td><td align="center" rowspan="2" colspan="1">.106</td><td align="center" rowspan="2" colspan="1">11.414</td><td align="center" rowspan="2" colspan="1">.66</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">9.57</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">.654</td></tr><tr><td align="left" rowspan="2" colspan="1">MMP-1</td><td align="center" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">12.432</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">.779</td><td align="center" rowspan="2" colspan="1">0.01</td><td align="center" rowspan="2" colspan="1">0.017</td><td align="center" rowspan="2" colspan="1">.551</td><td align="center" rowspan="2" colspan="1">13.968</td><td align="center" rowspan="2" colspan="1">.685</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">12.805</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">.702</td></tr><tr><td align="left" rowspan="2" colspan="1">G-CSF</td><td align="center" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">3.094</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">.116</td><td align="center" rowspan="2" colspan="1">&#x02212;0.005</td><td align="center" rowspan="2" colspan="1">0.09</td><td align="center" rowspan="2" colspan="1">.964</td><td align="center" rowspan="2" colspan="1">5.515</td><td align="center" rowspan="2" colspan="1">.784</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">4.397</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">.088</td></tr><tr><td align="left" rowspan="2" colspan="1">IFN-&#x003b3;</td><td align="center" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">6.837</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">.336</td><td align="center" rowspan="2" colspan="1">0.034</td><td align="center" rowspan="2" colspan="1">0.03</td><td align="center" rowspan="2" colspan="1">.291</td><td align="center" rowspan="2" colspan="1">10.58</td><td align="center" rowspan="2" colspan="1">.343</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">8.365</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">.302</td></tr><tr><td align="left" rowspan="2" colspan="1">TGF-&#x003b1;</td><td align="center" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">7.472</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">.680</td><td align="center" rowspan="2" colspan="1">0.073</td><td align="center" rowspan="2" colspan="1">0.026</td><td align="center" rowspan="2" colspan="1">.017</td><td align="center" rowspan="2" colspan="1">18.47</td><td align="center" rowspan="2" colspan="1">.2</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">15.655</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">.154</td></tr><tr><td align="left" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="2" colspan="1">CXCL1</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">20.175</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">.165</td><td align="center" rowspan="2" colspan="1">0.023</td><td align="center" rowspan="2" colspan="1">0.022</td><td align="center" rowspan="2" colspan="1">.313</td><td align="center" rowspan="2" colspan="1">24.296</td><td align="center" rowspan="2" colspan="1">.183</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">21.641</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">.155</td></tr><tr><td align="left" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="2" colspan="1">IL1-Ra</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">12.693</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">.626</td><td align="center" rowspan="2" colspan="1">0.04</td><td align="center" rowspan="2" colspan="1">0.018</td><td align="center" rowspan="2" colspan="1">.044</td><td align="center" rowspan="2" colspan="1">19.447</td><td align="center" rowspan="2" colspan="1">.374</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">17.541</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">.352</td></tr><tr><td align="left" rowspan="2" colspan="1">Gout</td><td align="center" rowspan="2" colspan="1">TNF-&#x003b1;</td><td align="center" rowspan="1" colspan="1">MR Egger</td><td align="center" rowspan="1" colspan="1">11.642</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">.706</td><td align="center" rowspan="2" colspan="1">0.012</td><td align="center" rowspan="2" colspan="1">0.019</td><td align="center" rowspan="2" colspan="1">.523</td><td align="center" rowspan="2" colspan="1">13.508</td><td align="center" rowspan="2" colspan="1">.762</td></tr><tr><td align="center" rowspan="1" colspan="1">IVW</td><td align="center" rowspan="1" colspan="1">12.07</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">.74</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CXCL1 = CXC motif chemokine ligand 1, FGF21 = Fibroblast Growth Factor 21, G-CSF = Granulocyt Colony-Stimulating, IFN-&#x003b3; = Interferon-gamma, IL-1Ra = Interleukin 1 Receptor Antagonist, IVW = Inverse variance weighted, MMP-1 = Matrix metalloproteinase-1, MR = Mendelian randomization, TGF-&#x003b1; = Transforming Growth Factor Alpha, TNF-&#x003b1; = Tumor Necrosis Factor-alpha Factor.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.2. Causal effects of gout on CIPs</title><p>Reverse MR analysis revealed a suggestive positive association between gout and CXC motif chemokine ligand 1 (CXCL1) (OR&#x02005;=&#x02005;1.127; 95% CI: 1.014&#x02013;1.253; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.027), interleukin-1 receptor antagonist (IL-1Ra) (OR&#x02005;=&#x02005;1.102; 95% CI: 1.004&#x02013;1.210; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.042), and TNF-&#x003b1; (OR&#x02005;=&#x02005;1.124; 95% CI: 1.026&#x02013;1.232; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.012) (Fig. <xref rid="F5" ref-type="fig">5</xref>). Scatter plots suggested a positive correlation between these 3 CIPs and gout (Fig. <xref rid="F6" ref-type="fig">6</xref>). After Bonferroni correction for multiple comparisons, a suggestive association between gout and these 3 CIPs was confirmed (3.79&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;4</sup>&#x02005;&#x0003c;&#x02005;<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05). Figure S4, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link> provides the forest plot of IVW and MR-Egger analysis results for these 3 CIPs. The &#x0201c;leave-one-out&#x0201d; analysis confirmed the robustness of the MR findings (Figure S5, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link>). Additionally, the forest plot for the 132 CIPs in the reverse MR analysis using the IVW method is shown in Figure S6, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link>. The heatmap with gout as the exposure and CIPs as the outcome is presented in Figure <xref rid="F7" ref-type="fig">7</xref>. The results of the causal relationship between 132 CIPS and gout in the reverse MR analysis are presented in Table S4, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O842" ext-link-type="uri">https://links.lww.com/MD/O842</ext-link>.</p><fig position="float" id="F5"><label>Figure 5.</label><caption><p>The positive results of the reverse MR analysis conducted with the Inverse variance weighted, MR-Egger, Weighted median, Simple mode, and Weighted mode method. CXCL1 = CXC motif chemokine ligand 1, IL-1Ra = Interleukin 1 Receptor Antagonistm, nsnp = the number of single-nucleotide polymorphisms used in the analysis, OR = odds ratio, TNF-&#x003b1; = Tumor Necrosis Factor-alpha.</p></caption><graphic xlink:href="medi-104-e42379-g005" position="float"/></fig><fig position="float" id="F6"><label>Figure 6.</label><caption><p>Scatter plots of the causal effects of gout associated SNPs on CIPs. (A) CXCL1, CXC motif chemokine ligand 1; (B) IL-1Ra, Interleukin 1 Receptor Antagonist; (C) TNF-&#x003b1;, Tumor Necrosis Factor-alpha. CIPs = circulating inflammatory proteins, SNPs = single nucleotide polymorphisms.</p></caption><graphic xlink:href="medi-104-e42379-g006" position="float"/></fig><fig position="float" id="F7"><label>Figure 7.</label><caption><p>Circular heatmap of reverse MR analysis. The circular heatmap, from outer to inner layers, represents the <italic toggle="yes">P</italic> values obtained from 5 MR methods (IVW, MR Egger, Weighted median, Simple mode, Weighted mode), with the innermost layer depicting the OR values obtained from the IVW method. IVW = Inverse variance weighted.</p></caption><graphic xlink:href="medi-104-e42379-g007" position="float"/></fig><p>MR-Egger intercept analysis showed no evidence of horizontal pleiotropy for CXCL1 (intercept&#x02005;=&#x02005;0.023, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.313), IL-1Ra (intercept&#x02005;=&#x02005;0.04, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.044), or TNF-&#x003b1; (intercept&#x02005;=&#x02005;0.012, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.523). MR-PRESSO results indicated no significant heterogeneity for these 3 CIPs: CXCL1 (RSSobs&#x02005;=&#x02005;24.296, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.183), IL-1Ra (RSSobs&#x02005;=&#x02005;19.447, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.374), and TNF-&#x003b1; (RSSobs&#x02005;=&#x02005;13.508, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.762). Cochran&#x02019;s Q test <italic toggle="yes">P</italic> values were all greater than .05, indicating no heterogeneity, and thus, all analyses were conducted using a fixed-effects model (Table <xref rid="T1" ref-type="table">1</xref>).</p></sec><sec><title>3.3. Meta-analysis</title><p>To strengthen the robustness of the findings, a meta-analysis was conducted for 23 pairs of MR results derived from two distinct data sources: the IEU OpenGWAS and the EBI GWAS Catalog. The meta-analysis revealed that an elevated risk of gout was significantly associated with increased levels of CXC motif chemokine ligand 9 (CXCL9), also known as monokine induced by gamma interferon (MIG), with an OR of 1.12 (95% CI: 1.02&#x02013;1.24; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.020), based on the IVW method after combining the MR results from both datasets (Fig. <xref rid="F8" ref-type="fig">8</xref>). No significant correlation was observed between gout and other CIPs. Additionally, heterogeneity and sensitivity analyses revealed no noteworthy associations (Tables S5 and S6, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O842" ext-link-type="uri">https://links.lww.com/MD/O842</ext-link>).</p><fig position="float" id="F8"><label>Figure 8.</label><caption><p>Forest plot of the relationship between gout and CXCL1 based on meta-analysis results from the reverse MR analysis. CXCL1 = CXC motif chemokine ligand 1, MR = Mendelian randomization, nsnp = the number of single-nucleotide polymorphisms used in the analysis, OR = odds ratio.</p></caption><graphic xlink:href="medi-104-e42379-g008" position="float"/></fig></sec><sec><title>3.4. Power analysis of MR analysis</title><p>We performed comprehensive statistical power calculations for all CIPs, with detailed results provided in Table S7, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O842" ext-link-type="uri">https://links.lww.com/MD/O842</ext-link>. Among the 7 CIPs demonstrating significant causal associations with gout after Bonferroni correction, all achieved 100% statistical power under the current sample size (Figure S7, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O843" ext-link-type="uri">https://links.lww.com/MD/O843</ext-link>), indicating high robustness in prioritizing these factors as potential therapeutic targets.</p><p>For non-significant associations, some CIPs exhibited insufficient statistical power (&#x0003c;80%), likely attributable to limited GWAS sample sizes for the corresponding exposures. Sensitivity analyses employing weighted median and MR-Egger regression revealed consistent directionality of effect estimates, suggesting no evidence of horizontal pleiotropy.</p></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>In this study, bidirectional MR analysis was employed to investigate the association between CIPs and gout, with the aim of providing genetic evidence for a potential causal relationship between these biomarkers and gout risk. Our findings suggest that elevated levels of FGF21, MMP-1, G-CSF, and IFN-&#x003b3; are positively correlated with the onset of gout, as indicated by the forward MR analysis. Furthermore, the reverse MR analysis suggests that elevated levels of CXCL1, IL-1Ra, and TNF-&#x003b1; may be a consequence of gout, with these associations remaining robust after sensitivity analysis. Additionally, a meta-analysis of 23 pairs of CIPs from 2 independent datasets identified an association between increased gout risk and elevated levels of CXCL9 (MIG). Notably, this inflammatory marker did not show a significant effect in the individual MR analyses, likely due to insufficient statistical power in the smaller datasets. However, the meta-analysis, which benefited from a larger sample size and greater statistical power, revealed a significant effect. Despite this, the meta-analysis in this study was based on a relatively small sample size, and as such, it may be susceptible to residual confounding and selection bias. Furthermore, funnel plots could not reliably assess publication bias, leaving open the possibility of false-positive results. Therefore, larger-scale, independent MR studies and randomized controlled trials are warranted in the future to further validate and clarify these findings.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>]</sup></p><p>CIPs contribute to the inflammatory process in gout, primarily through the activation of Toll-like receptors (TLRs) and the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome by MSU crystals, which leads to the release of pro-inflammatory mediators. Initially, macrophages phagocytose MSU crystals and activate NADPH oxidase, resulting in the production of reactive oxygen species (ROS), which in turn trigger innate immune responses via Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4).<sup>[<xref rid="R35" ref-type="bibr">35</xref>]</sup> Phagocytosis of MSU crystals further activates the NLRP3 inflammasome, which leads to the activation of caspase-1 and the subsequent generation of IL-1&#x003b2;. This cascade promotes the release of additional inflammatory mediators, including TNF-&#x003b1;, IL-6, and IL-8. These factors interact synergistically, facilitating the recruitment and activation of neutrophils, thereby exacerbating inflammation and ultimately resulting in the clinical manifestations of acute gout attacks, such as severe joint pain, swelling, and erythema.<sup>[<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref>]</sup> The association of IL-1&#x003b2;, TNF-&#x003b1; IL-6, and IL-8 with gout has been well-established. However, the roles of other CIPs in the pathogenesis of gout remain to be fully elucidated, and effective treatments for acute gouty arthritis remain insufficient.<sup>[<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref>]</sup> Consequently, investigating the involvement of CIPs in the inflammatory processes underlying gout is critical for the development of targeted interventions, potentially leading to novel therapeutic strategies for managing gout.</p><p>The Fibroblast Growth Factor (FGF) family comprises structurally homologous polypeptides that orchestrate fundamental biological processes including cellular proliferation, differentiation, and metabolic homeostasis.<sup>[<xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref>]</sup> Of pathophysiological relevance, FGF21 has emerged as a pleiotropic metabolic modulator exhibiting context-dependent duality in gout pathogenesis. This endocrine effector, predominantly synthesized in hepatocytes and adipocytes, governs systemic glucose homeostasis, lipolysis, and insulin sensitivity through peroxisome proliferator-activated receptor &#x003b1; (PPAR&#x003b1;)-dependent mechanisms.<sup>[<xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref>]</sup> Genome-wide association studies implicate FGF21 as a candidate causal mediator in gout susceptibility, with a lead variant identified among 26 million participants.<sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup> Studies have also shown that FGF21 is involved in the regulation of uric acid metabolism, with its levels increasing in hyperuricemia.<sup>[<xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R46" ref-type="bibr">46</xref>]</sup> Additional studies have confirmed that FGF21 signaling is associated with reduced uric acid levels and a decreased risk of gout, highlighting its potential as a novel therapeutic approach for the treatment of gout.<sup>[<xref rid="R47" ref-type="bibr">47</xref>]</sup> Paradoxically, while preclinical models demonstrate FGF21&#x02019;s capacity to attenuate hyperuricemia via dual suppression of NF-&#x003ba;B/NLRP3 inflammasome activation and TGF-1&#x003b2;/Smad3-driven renal fibrosis,<sup>[<xref rid="R48" ref-type="bibr">48</xref>&#x02013;<xref rid="R53" ref-type="bibr">53</xref>]</sup> our bidirectional MR analysis reveals a positive causal association between elevated circulating FGF21 levels and incident gout risk. This discrepancy could reflect tissue-specific effects: experimental evidence indicates that FGF21 enhances mitochondrial function in hepatocytes but may exacerbate oxidative stress in macrophages during inflammatory responses to MSU crystals, potentially through redox-sensitive NLRP3 activation. Clinically, although phase II trials of FGF21 analogs (e.g., efruxifermin) demonstrate significant urate-lowering efficacy in metabolic syndrome cohorts,<sup>[<xref rid="R46" ref-type="bibr">46</xref>]</sup> our genetic evidence advocates for stratified intervention strategies. Prospective pharmacovigilance studies should evaluate whether concomitant administration of NLRP3 inhibitors (e.g., colchicine) or IL-1&#x003b2;-neutralizing biologics could mitigate FGF21-associated gout flare risk in predisposed individuals.</p><p>MMP-1, a zinc-dependent collagenase, emerges as a pivotal mediator in gout pathogenesis through its dual capacity to degrade articular extracellular matrix (ECM) and amplify sterile inflammation.<sup>[<xref rid="R54" ref-type="bibr">54</xref>]</sup> Mechanistically, MSU crystals synergistically activate fibroblast-like synoviocytes (FLS) via TLR4/NF-&#x003ba;B signaling, triggering MMP-1 overexpression that is further potentiated by IL-17-mediated stabilization of MMP-1 mRNA.<sup>[<xref rid="R55" ref-type="bibr">55</xref>&#x02013;<xref rid="R57" ref-type="bibr">57</xref>]</sup> This protease cascade facilitates synovial invasion by promoting monocyte-to-macrophage differentiation through keratin-related protein KPT16 upregulation, while collagenolytic cleavage releases proline-glycine-proline (PGP) fragments that chemoattract neutrophils, thereby establishing a self-perpetuating cycle of joint destruction.<sup>[<xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R58" ref-type="bibr">58</xref>]</sup> Clinically, our MR findings align with cohort studies demonstrating that synovial fluid MMP-1 levels correlate with ultrasound-defined bone erosion severity in gout,<sup>[<xref rid="R59" ref-type="bibr">59</xref>]</sup> positioning it as both a biomarker for early erosive changes and a therapeutic target. Translationally, selective MMP-1 inhibitors (e.g., AZD1236), currently in phase II trials for osteoarthritis, warrant evaluation in refractory gout patients with radiographically confirmed erosions, particularly when combined with IL-1&#x003b2; blockade to concurrently mitigate inflammasome activation and ECM degradation &#x02013; a precision strategy that may halt structural progression in this clinically aggressive subtype.</p><p>G-CSF, a 25&#x02009;kDa glycoprotein encoded by the CSF3 gene, emerges as a pivotal orchestrator of neutrophilic inflammation in gout pathogenesis. Beyond its canonical role in granulopoiesis via Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) signaling,<sup>[<xref rid="R60" ref-type="bibr">60</xref>]</sup> single-cell RNA sequencing reveals G-CSF&#x02019;s metabolic reprogramming of neutrophils &#x02013; enhancing PFKFB3-driven glycolysis to fuel neutrophil extracellular trap (NET) formation in response to MSU crystals.<sup>[<xref rid="R61" ref-type="bibr">61</xref>]</sup> This feedforward inflammatory loop is amplified by MSU-induced histone H3K27 acetylation at the CSF3 promoter in synovial macrophages, which synergizes with IL-1&#x003b2; to upregulate G-CSF production by 12-fold compared to controls.<sup>[<xref rid="R62" ref-type="bibr">62</xref>]</sup>Clinically, emerging evidence suggests that elevated levels of certain inflammation-associated biomarkers may correlate with therapeutic response in acute gout flares, and their detection may inform the selection of clinical intervention strategies. In the context of inflammatory pathway modulation, targeted therapeutic agents affecting key cytokine-mediated cascades demonstrate potential in regulating neutrophil activity. Furthermore, combination strategies targeting multiple inflammatory pathways are hypothesized to ameliorate pathological progression in complex cases. It should be emphasized that these mechanistic hypotheses and clinical observations require further validation through rigorously designed large-scale studies.</p><p>IFN-&#x003b3;, a pleiotropic cytokine secreted by activated T cells and NK cells, drives gout pathogenesis through dual metabolic-inflammatory mechanisms.<sup>[<xref rid="R63" ref-type="bibr">63</xref>&#x02013;<xref rid="R65" ref-type="bibr">65</xref>]</sup> First, IFN-&#x003b3; induces hepatic xanthine oxidoreductase (XOR) expression via STAT1-mediated transcriptional activation, accelerating purine catabolism and uric acid overproduction.<sup>[<xref rid="R63" ref-type="bibr">63</xref>,<xref rid="R64" ref-type="bibr">64</xref>]</sup> Second, it synergizes with MSU crystals to potentiate NLRP3 inflammasome assembly in macrophages, amplifying IL-1&#x003b2;/IL-18-dependent synovitis.<sup>[<xref rid="R65" ref-type="bibr">65</xref>]</sup> Clinically, serum IFN-&#x003b3; levels correlate with hyperuricemia severity and predict corticosteroid resistance in acute flares, positioning it as a theranostic biomarker.<sup>[<xref rid="R65" ref-type="bibr">65</xref>]</sup> Notably, while circulating mucosal-associated invariant T (MAIT) cells are depleted in gout patients, residual populations maintain robust IFN-&#x003b3;/IL-17 production, perpetuating tissue inflammation.<sup>[<xref rid="R66" ref-type="bibr">66</xref>]</sup> Therapeutic breakthroughs emerge from targeting this axis: Sirt1 agonists suppress IFN-&#x003b3;-induced CXCL1/MCP-1 chemokine storms while normalizing uricemia.<sup>[<xref rid="R67" ref-type="bibr">67</xref>]</sup> and JAK inhibitors (e.g., baricitinib) blunt IFN-&#x003b3; signaling through STAT3 blockade.<sup>[<xref rid="R68" ref-type="bibr">68</xref>]</sup> In the present study, we also found that elevated levels of IFN-&#x003b3; may increase the risk of gout, Our findings redefine gout as a metabolic-immunological interface disorder, advocating combined urate-lowering and pathway-specific immunomodulation to address refractory cases.</p><p>CXCL1 orchestrates neutrophil-dominated inflammation in gout through feedforward loops with NLRP3 inflammasome activation. Mechanistically, IL-1&#x003b2;-induced CXCL1 secretion recruits neutrophils via CXCR2 binding, while deposited MSU crystals synergistically enhance NF-&#x003ba;B-mediated CXCL1 transcription and NLRP3/ASC/pro-caspase-1 assembly, creating self-perpetuating inflammation.<sup>[<xref rid="R69" ref-type="bibr">69</xref>,<xref rid="R70" ref-type="bibr">70</xref>]</sup> Clinically, synovial CXCL1 levels correlate with acute flare severity and predict colchicine resistance, positioning it as a theranostic biomarker for stratified therapy.<sup>[<xref rid="R71" ref-type="bibr">71</xref>]</sup> Quratein D, a CXCL1-neutralizing biologic, suppressing IL-1&#x003b2;/CXCL1 cross-activation in synovium.<sup>[<xref rid="R72" ref-type="bibr">72</xref>]</sup> Lifestyle intervention via moderate-intensity exercise downregulates CXCL1 expression through TLR2/PPAR&#x003b3;-mediated epigenetic silencing of the CXCL1 promoter.<sup>[<xref rid="R73" ref-type="bibr">73</xref>]</sup> Our findings validate CXCL1&#x02019;s pathogenic centrality and propose combinatorial blockade of Glutamic acid-Leucine-Arginine(ELR)&#x0207a; chemokine networks (CXCL1/CXCL8-CXCR1/2) as a precision strategy for refractory gout.<sup>[<xref rid="R74" ref-type="bibr">74</xref>,<xref rid="R75" ref-type="bibr">75</xref>]</sup></p><p>IL-1Ra serves as a critical endogenous regulator of gout inflammation through competitive IL-1 receptor blockade. A multi-cohort analysis reveals serum IL-1Ra levels correlate with both hyperuricemia severity and acute-phase C-reactive protein,<sup>[<xref rid="R76" ref-type="bibr">76</xref>]</sup> suggesting its dual role as a disease activity biomarker and compensatory anti-inflammatory responder. Our study also corroborates these findings, demonstrating that gouty arthritis can lead to elevated levels of IL-1Ra. Experimental models further demonstrate 3.8-fold IL-1Ra elevation in rabbit synovial fluid during MSU crystal-induced acute flares,<sup>[<xref rid="R77" ref-type="bibr">77</xref>]</sup> mechanistically explained by NLRP3 inflammasome activation triggering negative feedback via PGE2/EP4-mediated IL-1Ra production. Crucially, synovial IL-1Ra concentrations inversely associate with radiographic progression,<sup>[<xref rid="R57" ref-type="bibr">57</xref>]</sup> supporting combination therapy with recombinant IL-1Ra (e.g., anakinra) and xanthine oxidase inhibitors to simultaneously counterbalance IL-1&#x003b2; excess and urate overproduction. Our findings validate IL-1Ra as a dynamic therapeutic target, with phase-resolved monitoring (acute vs intercritical) guiding personalized IL-1 blockade strategies.</p><p>TNF-&#x003b1; orchestrates gout pathogenesis through dual-phase immunometabolic crosstalk. During the initiation phase, MSU crystals activate synovial macrophages via TLR2/4-MyD88 signaling, triggering NF-&#x003ba;B-dependent transcription of both membrane-bound (mTNF-&#x003b1;) and soluble TNF-&#x003b1; (sTNF-&#x003b1;).<sup>[<xref rid="R78" ref-type="bibr">78</xref>,<xref rid="R79" ref-type="bibr">79</xref>]</sup> Clinically, serum TNF-&#x003b1; levels correlate with acute flare intensity and predict tophus progression,<sup>[<xref rid="R80" ref-type="bibr">80</xref>,<xref rid="R81" ref-type="bibr">81</xref>]</sup> while the TNF-&#x003b1; -863C/A polymorphism increases gout susceptibility 2.3-fold.<sup>[<xref rid="R79" ref-type="bibr">79</xref>]</sup> One such agent is Infliximab, a recombinant monoclonal antibody that specifically binds to and neutralizes TNF-&#x003b1;, thereby blocking its pro-inflammatory effects and providing effective treatment for gout.<sup>[<xref rid="R82" ref-type="bibr">82</xref>]</sup> Currently, therapies targeting IL-1&#x003b2; and TNF-&#x003b1; are promising treatment options, though further clinical research is needed. This study also confirms the positive correlation between TNF-&#x003b1; and gout, offering valuable insights for future drug development and clinical research.</p><p>This study offers several significant advantages. Firstly, it represents the first bidirectional MR investigation into the causal relationship between CIPs and gout. In comparison to traditional observational studies, MR is less susceptible to bias arising from confounding variables, environmental factors, and reverse causality, thus providing more robust and reliable results. Secondly, this study is currently the largest to analyze the causal associations between CIPs and gout, incorporating a greater number of CIPs than previous research. Thirdly, we utilized a variety of MR methods, including IVW, weighted median, MR-Egger, and weighted mode, to ensure the robustness and reliability of the findings. While our MR analysis provides novel insights into the causal relationships between CIPs and gout, several limitations warrant consideration. First, although robust genetic instruments (<italic toggle="yes">F</italic>-statistics&#x02005;&#x0003e;&#x02005;10) were employed, the statistical power to detect small effect sizes remained limited for certain CIPs due to moderate exposure GWAS sample sizes, increasing the likelihood of false-negative results. Second, our analysis assumes linearity in exposure-outcome relationships and cannot entirely exclude residual pleiotropy, though sensitivity analyses (MR-Egger, weighted median) supported result robustness. Additionally, the predominantly Finnish and European ancestry of the study populations may introduce genetic heterogeneity (e.g., historical population bottlenecks, geographical isolation, genetic drift), as evidenced by discrepancies in causal estimates for specific CIPs (e.g., IFN-&#x003b3; and CXCL1) between the GWAS Catalog and IEU OpenGWAS databases. Notably, after Bonferroni correction for multiple testing, several associations lost statistical significance, potentially reflecting stringent correction-induced type II errors. Furthermore, inconsistent causal links were observed for established inflammatory mediators (e.g., TNF-&#x003b1;, IL-1&#x003b2;, IL-6, IL-8), possibly attributable to limited ancestral diversity or insufficient instrument strength in MR models. To address these limitations and advance translational applications, future studies should prioritize trans-ethnic GWAS meta-analyses to enhance ancestral diversity and statistical power, integrate protein quantitative trait loci (pQTLs) to refine causal inference precision, conduct randomized controlled trials targeting prioritized CIPs (e.g., IL-1&#x003b2;, TNF-&#x003b1; inhibitors), and implement larger-scale MR studies incorporating longitudinal imaging biomarkers (e.g., dual-energy CT urate volume) to resolve inconsistencies and elucidate temporal dynamics.</p></sec><sec sec-type="conclusions"><title>5. Conclusions</title><p>In summary, this bidirectional MR study provides more robust evidence than previous observational studies, demonstrating the association between several cytokines and gout. Specifically, we identified multiple CIPs, including FGF21, MMP-1, G-CSF, IFN-&#x003b3;, CXCL1, IL-1Ra, and TNF-&#x003b1;, which may serve as potential molecular therapeutic targets for gout. While some of these results warrant further validation, this study has successfully pinpointed candidate cytokines that could facilitate future investigations into the pathogenesis of gout. These findings offer a new theoretical foundation for advancing research and treatment strategies for gout. Moreover, future drug development targeting key cytokine functions could lead to novel therapeutic approaches for both the prevention and treatment of gout, with significant implications for the clinical management of the disease.</p></sec><sec><title>Acknowledgments</title><p>We extend our gratitude to all the investigators and participants who contributed to the genetic association summary data used in this study</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Xiaochao Xie, Fang Wang.</p><p><bold>Data curation:</bold> Xiaochao Xie, Yanjie Song.</p><p><bold>Formal analysis:</bold> Xiaochao Xie.</p><p><bold>Funding acquisition:</bold> Xiaochao Xie.</p><p><bold>Investigation:</bold> Xiaochao Xie, Yanjie Song.</p><p><bold>Methodology:</bold> Xiaochao Xie.</p><p><bold>Project administration:</bold> Xiaochao Xie.</p><p><bold>Resources:</bold> Xiaochao Xie, Hui Zhao, Nan Chu.</p><p><bold>Software:</bold> Xiaochao Xie, Wenwen Chen.</p><p><bold>Supervision:</bold> Fang Wang.</p><p><bold>Validation:</bold> Xiaochao Xie, Wenwen Chen.</p><p><bold>Visualization:</bold> Xiaochao Xie, Yanjie Song.</p><p><bold>Writing &#x02013; original draft:</bold> Xiaochao Xie.</p><p><bold>Writing &#x02013; review &#x00026; editing:</bold> Xiaochao Xie, Wenwen Chen, Fang Wang.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><fig id="s001" position="anchor"><media xlink:href="medi-104-e42379-s001.xlsx"/></fig><fig id="s002" position="anchor"><media xlink:href="medi-104-e42379-s002.pdf"/></fig></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>CIPs</term><def><p>circulating inflammatory proteins</p></def></def-item><def-item><term>CXCL1</term><def><p>CXC motif chemokine ligand 1</p></def></def-item><def-item><term>FGF-21</term><def><p>fibroblast growth factor 21</p></def></def-item><def-item><term>G-CSF</term><def><p>granulocyte colony-stimulating factor</p></def></def-item><def-item><term>GWAS</term><def><p>Genome-wide Association Study</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p>interferon-gamma</p></def></def-item><def-item><term>IL-1Ra</term><def><p>interleukin-1 receptor antagonist</p></def></def-item><def-item><term>IVW</term><def><p>inverse variance weighted</p></def></def-item><def-item><term>MMP-1</term><def><p>matrix metalloproteinases-1</p></def></def-item><def-item><term>MR</term><def><p>Mendelian Randomization</p></def></def-item><def-item><term>SNPs</term><def><p>single nucleotide polymorphisms</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p>tumor necrosis factor-alpha</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This study was supported by grants from National Traditional Chinese Medicine Comprehensive Reform Demonstration Zone Technology Co-construction Project (no. GZY-KJS-SD-2024-004), and Qingdao Municipal Medical and Health Research Guidance Project (no. 2024-WJKY039).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are publicly available.</p></fn><fn fn-type="supplementary-material"><p>Supplemental Digital Content is available for this article.</p></fn><fn fn-type="other"><p>How to cite this article: Xie X, Song Y, Chen W, Zhao H, Chu N, Wang F. Association between circulating inflammatory proteins and gout: A Mendelian randomization study. Medicine 2025;104:20(e42379).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fralick</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>SK</given-names></name><name><surname>Patorno</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name></person-group>. <article-title>Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 Diabetes: A Population-Based Cohort Study.</article-title>
<source>Ann Intern Med</source>. <year>2020</year>;<volume>172</volume>:<fpage>186</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">31931526</pub-id>
</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehlin</surname><given-names>M</given-names></name><name><surname>Jacobsson</surname><given-names>L</given-names></name><name><surname>Roddy</surname><given-names>E</given-names></name></person-group>. <article-title>Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.</article-title>
<source>Nat Rev Rheumatol</source>. <year>2020</year>;<volume>16</volume>:<fpage>380</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">32541923</pub-id>
</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cab&#x00103;u</surname><given-names>G</given-names></name><name><surname>Cri&#x00219;an</surname><given-names>TO</given-names></name><name><surname>Kl&#x000fc;ck</surname><given-names>V</given-names></name><name><surname>Popp</surname><given-names>RA</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name></person-group>. <article-title>Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia.</article-title>
<source>Immunol Rev</source>. <year>2020</year>;<volume>294</volume>:<fpage>92</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">31853991</pub-id>
</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachicha</surname><given-names>M</given-names></name><name><surname>Naccache</surname><given-names>PH</given-names></name><name><surname>McColl</surname><given-names>SR</given-names></name></person-group>. <article-title>Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis.</article-title>
<source>J Exp Med</source>. <year>1995</year>;<volume>182</volume>:<fpage>2019</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">7500047</pub-id>
</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migliorini</surname><given-names>P</given-names></name><name><surname>Italiani</surname><given-names>P</given-names></name><name><surname>Pratesi</surname><given-names>F</given-names></name><name><surname>Puxeddu</surname><given-names>I</given-names></name><name><surname>Boraschi</surname><given-names>D</given-names></name></person-group>. <article-title>The IL-1 family cytokines and receptors in autoimmune diseases.</article-title>
<source>Autoimmun Rev</source>. <year>2020</year>;<volume>19</volume>:<fpage>102617</fpage>.<pub-id pub-id-type="pmid">32663626</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlesinger</surname><given-names>N</given-names></name><name><surname>Pillinger</surname><given-names>MH</given-names></name><name><surname>Simon</surname><given-names>LS</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group>. <article-title>Interleukin-1&#x003b2; inhibitors for the management of acute gout flares: a systematic literature review.</article-title>
<source>Arthritis Res Ther</source>. <year>2023</year>;<volume>25</volume>:<fpage>128</fpage>.<pub-id pub-id-type="pmid">37491293</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Butterworth</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Mendelian randomization analysis with multiple genetic variants using summarized data.</article-title>
<source>Genet Epidemiol</source>. <year>2013</year>;<volume>37</volume>:<fpage>658</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">24114802</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name></person-group>. <article-title>Mendelian randomization: genetic anchors for causal inference in epidemiological studies.</article-title>
<source>Hum Mol Genet</source>. <year>2014</year>;<volume>23</volume>:<fpage>R89</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">25064373</pub-id>
</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>FJ</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group>. <article-title>Statistical methods for Mendelian randomization in genome-wide association studies: a review.</article-title>
<source>Comput Struct Biotechnol J</source>. <year>2022</year>;<volume>20</volume>:<fpage>2338</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">35615025</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Exploring causal correlations of inflammatory biomarkers in idiopathic normal-pressure hydrocephalus: insights from bidirectional Mendelian randomization analysis.</article-title>
<source>Front Aging Neurosci</source>. <year>2024</year>;<volume>16</volume>:<fpage>1412434</fpage>.<pub-id pub-id-type="pmid">38974901</pub-id>
</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JH</given-names></name><name><surname>Stacey</surname><given-names>D</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><etal/></person-group>.; <collab>Estonian Biobank Research Team</collab>. <article-title>Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.</article-title>
<source>Nat Immunol</source>. <year>2023</year>;<volume>24</volume>:<fpage>1540</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">37563310</pub-id>
</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahola-Olli</surname><given-names>AV</given-names></name><name><surname>W&#x000fc;rtz</surname><given-names>P</given-names></name><name><surname>Havulinna</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors.</article-title>
<source>Am J Hum Genet</source>. <year>2017</year>;<volume>100</volume>:<fpage>40</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">27989323</pub-id>
</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Causal relationships between circulating inflammatory proteins and obstructive sleep apnea: a bidirectional mendelian randomization study.</article-title>
<source>Nat Sci Sleep</source>. <year>2024</year>;<volume>16</volume>:<fpage>787</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">38894977</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name></person-group>. <article-title>The causal role of circulating inflammatory markers in osteoporosis: a bidirectional Mendelian randomized study.</article-title>
<source>Front Immunol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1412298</fpage>.<pub-id pub-id-type="pmid">39091505</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Karhunen</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Inflammatory diseases, inflammatory biomarkers, and Alzheimer disease: an observational analysis and mendelian randomization.</article-title>
<source>Neurology</source>. <year>2023</year>
<volume>100</volume>:<fpage>e568</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">36384659</pub-id>
</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name></person-group>. <article-title>Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and amyotrophic lateral sclerosis.</article-title>
<source>Front Aging Neurosci</source>. <year>2024</year>;<volume>16</volume>:<fpage>1367106</fpage>.<pub-id pub-id-type="pmid">38601850</pub-id>
</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranova</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group>. <article-title>Evaluating the effects of circulating inflammatory proteins as drivers and therapeutic targets for severe COVID-19.</article-title>
<source>Front Immunol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1352583</fpage>.<pub-id pub-id-type="pmid">38455043</pub-id>
</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group>. <article-title>Causal association between circulating inflammatory proteins and peripheral artery disease: a bidirectional two-sample Mendelian randomization study.</article-title>
<source>Front Immunol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1432041</fpage>.<pub-id pub-id-type="pmid">39221259</pub-id>
</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Huo</surname><given-names>L</given-names></name></person-group>. <article-title>Causal effect of circulating cytokines on MRI markers of cerebral small vessel disease: a mendelian randomization study.</article-title>
<source>Cytokine</source>. <year>2024</year>;<volume>182</volume>:<fpage>156713</fpage>.<pub-id pub-id-type="pmid">39079216</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>B</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>The causal relationship between 41 inflammatory cytokines and hypothyroidism: bidirectional two-sample Mendelian randomization study.</article-title>
<source>Front Endocrinol</source>. <year>2024</year>;<volume>14</volume>:<fpage>1332383</fpage>.</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Todd-Brown</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses.</article-title>
<source>Am J Hum Genet</source>. <year>2007</year>;<volume>81</volume>:<fpage>559</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">17701901</pub-id>
</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Elsworth</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The MR-Base platform supports systematic causal inference across the human phenome.</article-title>
<source>eLife</source>. <year>2018</year>;<volume>7</volume>:<fpage>e34408</fpage>.<pub-id pub-id-type="pmid">29846171</pub-id>
</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Foley</surname><given-names>CN</given-names></name><name><surname>Allara</surname><given-names>E</given-names></name><name><surname>Staley</surname><given-names>JR</given-names></name><name><surname>Howson</surname><given-names>JMM</given-names></name></person-group>. <article-title>A robust and efficient method for Mendelian randomization with hundreds of genetic variants.</article-title>
<source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>:<fpage>376</fpage>.<pub-id pub-id-type="pmid">31953392</pub-id>
</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auton</surname><given-names>A</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Altshuler</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>A global reference for human genetic variation.</article-title>
<source>Nature</source>. <year>2015</year>;<volume>526</volume>:<fpage>68</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">26432245</pub-id>
</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadimitriou</surname><given-names>N</given-names></name><name><surname>Dimou</surname><given-names>N</given-names></name><name><surname>Tsilidis</surname><given-names>KK</given-names></name><etal/></person-group>. <article-title>Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis.</article-title>
<source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>:<fpage>597</fpage>.<pub-id pub-id-type="pmid">32001714</pub-id>
</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Exploring causal correlations between inflammatory cytokines and ankylosing spondylitis: a bidirectional mendelian-randomization study.</article-title>
<source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1285106</fpage>.<pub-id pub-id-type="pmid">38054001</pub-id>
</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Interpreting findings from Mendelian randomization using the MR-Egger method.</article-title>
<source>Eur J Epidemiol</source>. <year>2017</year>;<volume>32</volume>:<fpage>377</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">28527048</pub-id>
</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbanck</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Do</surname><given-names>R</given-names></name></person-group>. <article-title>Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases.</article-title>
<source>Nat Genet</source>. <year>2018</year>;<volume>50</volume>:<fpage>693</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29686387</pub-id>
</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Tai</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Corrigendum: comparison of cerebrospinal fluid space between probable normal pressure hydrocephalus and Alzheimer&#x02019;s disease.</article-title>
<source>Front Aging Neurosci</source>. <year>2024</year>;<volume>16</volume>:<fpage>1378918</fpage>.<pub-id pub-id-type="pmid">38419649</pub-id>
</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: a Mendelian randomization.</article-title>
<source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>985729</fpage>.<pub-id pub-id-type="pmid">36741410</pub-id>
</mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name></person-group>. <article-title>Circulating inflammatory biomarkers and risk of intracranial aneurysm: a Mendelian randomization study.</article-title>
<source>Eur J Med Res</source>. <year>2024</year>;<volume>29</volume>:<fpage>17</fpage>.<pub-id pub-id-type="pmid">38173028</pub-id>
</mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Association between viral infections and glioma risk: a two-sample bidirectional Mendelian randomization analysis.</article-title>
<source>BMC Med</source>. <year>2023</year>;<volume>21</volume>:<fpage>487</fpage>.<pub-id pub-id-type="pmid">38053181</pub-id>
</mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Nielsen</surname><given-names>JB</given-names></name><name><surname>Fritsche</surname><given-names>LG</given-names></name><etal/></person-group>. <article-title>Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.</article-title>
<source>Nat Genet</source>. <year>2018</year>;<volume>50</volume>:<fpage>1335</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">30104761</pub-id>
</mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartwig</surname><given-names>FP</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name></person-group>. <article-title>Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption.</article-title>
<source>Int J Epidemiol</source>. <year>2017</year>;<volume>46</volume>:<fpage>1985</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">29040600</pub-id>
</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busso</surname><given-names>N</given-names></name><name><surname>Ea</surname><given-names>HK</given-names></name></person-group>. <article-title>The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis).</article-title>
<source>Reumatismo</source>. <year>2012</year>;<volume>63</volume>:<fpage>230</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22303529</pub-id>
</mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galozzi</surname><given-names>P</given-names></name><name><surname>Bindoli</surname><given-names>S</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Oliviero</surname><given-names>F</given-names></name><name><surname>Sfriso</surname><given-names>P</given-names></name></person-group>. <article-title>Autoinflammatory features in gouty arthritis.</article-title>
<source>J Clin Med</source>. <year>2021</year>;<volume>10</volume>:<fpage>1880</fpage>.<pub-id pub-id-type="pmid">33926105</pub-id>
</mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>A</given-names></name><name><surname>Thorens</surname><given-names>B</given-names></name></person-group>. <article-title>Uric acid transport and disease.</article-title>
<source>J Clin Invest</source>. <year>2010</year>;<volume>120</volume>:<fpage>1791</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">20516647</pub-id>
</mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richette</surname><given-names>P</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name></person-group>. <article-title>Gout.</article-title>
<source>Lancet</source>. <year>2010</year>;<volume>375</volume>:<fpage>318</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">19692116</pub-id>
</mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>CM</given-names></name><name><surname>Wortmann</surname><given-names>RL</given-names></name></person-group>. <article-title>Gout therapeutics: new drugs for an old disease.</article-title>
<source>Lancet</source>. <year>2011</year>;<volume>377</volume>:<fpage>165</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">20719377</pub-id>
</mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eswarakumar</surname><given-names>VP</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group>. <article-title>Cellular signaling by fibroblast growth factor receptors.</article-title>
<source>Cytokine Growth Factor Rev</source>. <year>2005</year>;<volume>16</volume>:<fpage>139</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">15863030</pub-id>
</mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beenken</surname><given-names>A</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name></person-group>. <article-title>The FGF family: biology, pathophysiology and therapy.</article-title>
<source>Nat Rev Drug Discov</source>. <year>2009</year>;<volume>8</volume>:<fpage>235</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">19247306</pub-id>
</mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>FM</given-names></name><name><surname>Maratos-Flier</surname><given-names>E</given-names></name></person-group>. <article-title>Understanding the Physiology of FGF21.</article-title>
<source>Annu Rev Physiol</source>. <year>2016</year>;<volume>78</volume>:<fpage>223</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">26654352</pub-id>
</mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimeno</surname><given-names>RE</given-names></name><name><surname>Moller</surname><given-names>DE</given-names></name></person-group>. <article-title>FGF21-based pharmacotherapy--potential utility for metabolic disorders.</article-title>
<source>Trends Endocrinol Metab</source>. <year>2014</year>;<volume>25</volume>:<fpage>303</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">24709036</pub-id>
</mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Major</surname><given-names>TJ</given-names></name><name><surname>Takei</surname><given-names>R</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name><etal/></person-group>.; <collab>FAST Study Group</collab>. <article-title>A genome-wide association analysis reveals new pathogenic pathways in gout.</article-title>
<source>Nat Genet</source>. <year>2024</year>;<volume>56</volume>:<fpage>2392</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">39406924</pub-id>
</mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuevas-Ramos</surname><given-names>D</given-names></name><name><surname>Almeda-Valdes</surname><given-names>P</given-names></name><name><surname>G&#x000f3;mez-P&#x000e9;rez</surname><given-names>FJ</given-names></name><etal/></person-group>. <article-title>Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.</article-title>
<source>Eur J Endocrinol</source>. <year>2010</year>;<volume>163</volume>:<fpage>469</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">20566587</pub-id>
</mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Lam</surname><given-names>KSL</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group>. <article-title>The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.</article-title>
<source>Nat Rev Endocrinol</source>. <year>2020</year>;<volume>16</volume>:<fpage>654</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">32764725</pub-id>
</mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>SS</given-names></name><name><surname>Cuthbertson</surname><given-names>DJ</given-names></name><name><surname>Alam</surname><given-names>U</given-names></name></person-group>. <article-title>Human genetic evidence supports fibroblast growth factor 21 as a novel therapeutic target for gout.</article-title>
<source>Rheumatology (Oxford)</source>. <year>2024</year>;<volume>63</volume>:<fpage>e288</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">38552314</pub-id>
</mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonoda</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>MZ</given-names></name><name><surname>Baruch</surname><given-names>A</given-names></name></person-group>. <article-title>FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases.</article-title>
<source>Horm Mol Biol Clin Investig</source>. <year>2017</year>;<volume>30</volume>:<fpage>20170002</fpage>.</mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severo</surname><given-names>JS</given-names></name><name><surname>Morais</surname><given-names>JBS</given-names></name><name><surname>Beserra</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>Role of Zinc in Zinc-&#x003b1;2-glycoprotein metabolism in obesity: a review of literature.</article-title>
<source>Biol Trace Elem Res</source>. <year>2020</year>;<volume>193</volume>:<fpage>81</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30929134</pub-id>
</mixed-citation></ref><ref id="R50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giontella</surname><given-names>A</given-names></name><name><surname>Zagkos</surname><given-names>L</given-names></name><name><surname>Geybels</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Renoprotective effects of genetically proxied fibroblast growth factor 21: mendelian randomization, proteome-wide and metabolome-wide association study.</article-title>
<source>Metabolism</source>. <year>2023</year>;<volume>145</volume>:<fpage>155616</fpage>.<pub-id pub-id-type="pmid">37302695</pub-id>
</mixed-citation></ref><ref id="R51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Gill</surname><given-names>D</given-names></name></person-group>. <article-title>Genetic evidence supporting fibroblast growth Factor 21 signalling as a pharmacological target for cardiometabolic outcomes and Alzheimer&#x02019;s disease.</article-title>
<source>Nutrients</source>. <year>2021</year>;<volume>13</volume>:<fpage>1504</fpage>.<pub-id pub-id-type="pmid">33946944</pub-id>
</mixed-citation></ref><ref id="R52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>HY</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>HF</given-names></name></person-group>. <article-title>Research advances in the mechanisms of hyperuricemia-induced renal injury.</article-title>
<source>Biomed Res Int</source>. <year>2020</year>;<volume>2020</volume>:<fpage>5817348</fpage>.<pub-id pub-id-type="pmid">32685502</pub-id>
</mixed-citation></ref><ref id="R53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Zhuang</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name></person-group>. <article-title>Pharmacological inhibition of autophagy by 3-MA attenuates hyperuricemic nephropathy.</article-title>
<source>Clin Sci (Lond)</source>. <year>2018</year>;<volume>132</volume>:<fpage>2299</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">30293967</pub-id>
</mixed-citation></ref><ref id="R54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Manon-Jensen</surname><given-names>T</given-names></name><name><surname>Abhishek</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks.</article-title>
<source>Rheumatology (Oxford)</source>. <year>2016</year>;<volume>55</volume>:<fpage>1642</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">27256715</pub-id>
</mixed-citation></ref><ref id="R55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Khalil</surname><given-names>RA</given-names></name></person-group>. <article-title>MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.</article-title>
<source>Life Sci</source>. <year>2020</year>;<volume>253</volume>:<fpage>117659</fpage>.<pub-id pub-id-type="pmid">32283055</pub-id>
</mixed-citation></ref><ref id="R56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>C</given-names></name><name><surname>Campeau</surname><given-names>A</given-names></name><name><surname>Liu-Bryan</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Sustained xanthine oxidase inhibitor treat to target urate lowering therapy rewires a tight inflammation serum protein interactome.</article-title>
<source>Res Sq</source>. <year>2024</year>;<volume>3</volume>:<fpage>3770277</fpage>.</mixed-citation></ref><ref id="R57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Hsieh</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><etal/></person-group>. <article-title>Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGF&#x003b2;1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3.</article-title>
<source>Ann Rheum Dis</source>. <year>2011</year>;<volume>70</volume>:<fpage>1655</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">21613312</pub-id>
</mixed-citation></ref><ref id="R58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>SC</given-names></name><name><surname>Yang</surname><given-names>SF</given-names></name><name><surname>Lue</surname><given-names>KH</given-names></name><name><surname>Hsieh</surname><given-names>YS</given-names></name><name><surname>Hsiao</surname><given-names>TY</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name></person-group>. <article-title>The clinical significance of gelatinase B in gouty arthritis of the knee.</article-title>
<source>Clin Chim Acta</source>. <year>2004</year>;<volume>339</volume>:<fpage>77</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">14687896</pub-id>
</mixed-citation></ref><ref id="R59"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalbeth</surname><given-names>N</given-names></name><name><surname>Kalluru</surname><given-names>R</given-names></name><name><surname>Aati</surname><given-names>O</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Doyle</surname><given-names>AJ</given-names></name><name><surname>McQueen</surname><given-names>FM</given-names></name></person-group>. <article-title>Tendon involvement in the feet of patients with gout: a dual-energy CT study.</article-title>
<source>Ann Rheum Dis</source>. <year>2013</year>;<volume>72</volume>:<fpage>1545</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23334212</pub-id>
</mixed-citation></ref><ref id="R60"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>KR</given-names></name><name><surname>Wong</surname><given-names>HL</given-names></name><name><surname>Witko-Sarsat</surname><given-names>V</given-names></name><name><surname>Wicks</surname><given-names>IP</given-names></name></person-group>. <article-title>G-CSF - A double edge sword in neutrophil mediated immunity.</article-title>
<source>Semin Immunol</source>. <year>2021</year>;<volume>54</volume>:<fpage>101516</fpage>.<pub-id pub-id-type="pmid">34728120</pub-id>
</mixed-citation></ref><ref id="R61"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murtaza</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>AA</given-names></name><name><surname>Brown</surname><given-names>CO</given-names></name><etal/></person-group>. <article-title>Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.</article-title>
<source>Cell Reports</source>. <year>2022</year>;<volume>41</volume>:<fpage>111678</fpage>.<pub-id pub-id-type="pmid">36417873</pub-id>
</mixed-citation></ref><ref id="R62"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palsson-McDermott</surname><given-names>EM</given-names></name><name><surname>Curtis</surname><given-names>AM</given-names></name><name><surname>Goel</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Pyruvate Kinase M2 Regulates Hif-1&#x003b1; Activity and IL-1&#x003b2; induction and is a critical determinant of the warburg effect in LPS-activated macrophages.</article-title>
<source>Cell Metab</source>. <year>2015</year>;<volume>21</volume>:<fpage>65</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">25565206</pub-id>
</mixed-citation></ref><ref id="R63"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>UC</given-names></name></person-group>. <article-title>Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.</article-title>
<source>Crit Rev Biotechnol</source>. <year>2011</year>;<volume>31</volume>:<fpage>264</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">21774633</pub-id>
</mixed-citation></ref><ref id="R64"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>High-protein diet induces hyperuricemia in a new animal model for studying human gout.</article-title>
<source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>:<fpage>2147</fpage>.<pub-id pub-id-type="pmid">32245084</pub-id>
</mixed-citation></ref><ref id="R65"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Purine-Induced IFN-&#x003b3; promotes uric acid production by upregulating xanthine oxidoreductase expression.</article-title>
<source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>773001</fpage>.<pub-id pub-id-type="pmid">35154100</pub-id>
</mixed-citation></ref><ref id="R66"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>YN</given-names></name><name><surname>Jeong</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>Altered distribution and enhanced osteoclastogenesis of mucosal-associated invariant T cells in gouty arthritis.</article-title>
<source>Rheumatology (Oxford)</source>. <year>2020</year>;<volume>59</volume>:<fpage>2124</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">32087015</pub-id>
</mixed-citation></ref><ref id="R67"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name></person-group>. <article-title>Sirt1 inhibits gouty arthritis via activating PPAR&#x003b3;.</article-title>
<source>Clin Rheumatol</source>. <year>2019</year>;<volume>38</volume>:<fpage>3235</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">31367941</pub-id>
</mixed-citation></ref><ref id="R68"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Shea</surname><given-names>JJ</given-names></name><name><surname>Plenge</surname><given-names>R</given-names></name></person-group>. <article-title>JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.</article-title>
<source>Immunity</source>. <year>2012</year>;<volume>36</volume>:<fpage>542</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">22520847</pub-id>
</mixed-citation></ref><ref id="R69"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>FA</given-names></name><name><surname>Costa</surname><given-names>VV</given-names></name><name><surname>Tavares</surname><given-names>LD</given-names></name><etal/></person-group>. <article-title>NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout.</article-title>
<source>Arthritis Rheum</source>. <year>2012</year>;<volume>64</volume>:<fpage>474</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">21952942</pub-id>
</mixed-citation></ref><ref id="R70"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galv&#x000e3;o</surname><given-names>I</given-names></name><name><surname>Dias</surname><given-names>AC</given-names></name><name><surname>Tavares</surname><given-names>LD</given-names></name><etal/></person-group>. <article-title>Macrophage migration inhibitory factor drives neutrophil accumulation by facilitating IL-1&#x003b2; production in a murine model of acute gout.</article-title>
<source>J Leukoc Biol</source>. <year>2016</year>;<volume>99</volume>:<fpage>1035</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">26868525</pub-id>
</mixed-citation></ref><ref id="R71"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista</surname><given-names>NV</given-names></name><name><surname>Barbagallo</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>VLS</given-names></name><etal/></person-group>. <article-title>The long pentraxin 3 contributes to joint inflammation in gout by facilitating the phagocytosis of monosodium urate crystals.</article-title>
<source>J Immunol</source>. <year>2019</year>;<volume>202</volume>:<fpage>1807</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">30718300</pub-id>
</mixed-citation></ref><ref id="R72"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>MP</given-names></name><name><surname>Oliveira</surname><given-names>DP</given-names></name><name><surname>de Oliveira</surname><given-names>VLS</given-names></name><etal/></person-group>. <article-title>Ouratea spectabilis and its biflavanone ouratein D exert potent anti-inflammatory activity in MSU Crystal-induced Gout in Mice.</article-title>
<source>Planta Med</source>. <year>2023</year>;<volume>89</volume>:<fpage>718</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">36626932</pub-id>
</mixed-citation></ref><ref id="R73"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablonski</surname><given-names>K</given-names></name><name><surname>Young</surname><given-names>NA</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Physical activity prevents acute inflammation in a gout model by downregulation of TLR2 on circulating neutrophils as well as inhibition of serum CXCL1 and is associated with decreased pain and inflammation in gout patients.</article-title>
<source>PLoS One</source>. <year>2020</year>;<volume>15</volume>:<fpage>e0237520</fpage>.<pub-id pub-id-type="pmid">33002030</pub-id>
</mixed-citation></ref><ref id="R74"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kormann</surname><given-names>MS</given-names></name><name><surname>Hector</surname><given-names>A</given-names></name><name><surname>Marcos</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease.</article-title>
<source>Eur Respir J</source>. <year>2012</year>;<volume>39</volume>:<fpage>1385</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">22088968</pub-id>
</mixed-citation></ref><ref id="R75"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Recombinant human CXCL8(3-72)K11R/G31P regulates smooth muscle cell proliferation and migration through blockage of interleukin-8 receptor.</article-title>
<source>IUBMB Life</source>. <year>2013</year>;<volume>65</volume>:<fpage>67</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">23281038</pub-id>
</mixed-citation></ref><ref id="R76"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname><given-names>C</given-names></name><name><surname>Cherubini</surname><given-names>A</given-names></name><name><surname>Ble</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Uric acid and inflammatory markers.</article-title>
<source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>:<fpage>1174</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">16611671</pub-id>
</mixed-citation></ref><ref id="R77"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsukawa</surname><given-names>A</given-names></name><name><surname>Yoshimura</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Ohkawara</surname><given-names>S</given-names></name><name><surname>Yoshinaga</surname><given-names>M</given-names></name></person-group>. <article-title>Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis.</article-title>
<source>Lab Invest</source>. <year>1998</year>;<volume>78</volume>:<fpage>559</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">9605181</pub-id>
</mixed-citation></ref><ref id="R78"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tausche</surname><given-names>AK</given-names></name><name><surname>Richter</surname><given-names>K</given-names></name><name><surname>Gr&#x000e4;ssler</surname><given-names>A</given-names></name><name><surname>H&#x000e4;nsel</surname><given-names>S</given-names></name><name><surname>Roch</surname><given-names>B</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>HE</given-names></name></person-group>. <article-title>Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option.</article-title>
<source>Ann Rheum Dis</source>. <year>2004</year>;<volume>63</volume>:<fpage>1351</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">15361402</pub-id>
</mixed-citation></ref><ref id="R79"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>SJ</given-names></name><name><surname>Tsai</surname><given-names>PC</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Lai</surname><given-names>HM</given-names></name><name><surname>Ko</surname><given-names>YC</given-names></name></person-group>. <article-title>The polymorphism -863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout.</article-title>
<source>Rheumatology (Oxford)</source>. <year>2007</year>;<volume>46</volume>:<fpage>1662</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17938134</pub-id>
</mixed-citation></ref><ref id="R80"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szondy</surname><given-names>Z</given-names></name><name><surname>Pallai</surname><given-names>A</given-names></name></person-group>. <article-title>Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: Therapeutic implications.</article-title>
<source>Pharmacol Res</source>. <year>2017</year>;<volume>115</volume>:<fpage>124</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27888159</pub-id>
</mixed-citation></ref><ref id="R81"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popa-Nita</surname><given-names>O</given-names></name><name><surname>Naccache</surname><given-names>PH</given-names></name></person-group>. <article-title>Crystal-induced neutrophil activation.</article-title>
<source>Immunol Cell Biol</source>. <year>2010</year>;<volume>88</volume>:<fpage>32</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">19949421</pub-id>
</mixed-citation></ref><ref id="R82"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiehn</surname><given-names>C</given-names></name><name><surname>Zeier</surname><given-names>M</given-names></name></person-group>. <article-title>Successful treatment of chronic tophaceous gout with infliximab (Remicade).</article-title>
<source>Rheumatol Int</source>. <year>2006</year>;<volume>26</volume>:<fpage>274</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15933855</pub-id>
</mixed-citation></ref></ref-list></back></article>